AQILION AB (publ) today announces that the company has divested its entire holding in Oncorena Holding AB. The decision is in line with Aqilion’s strategy to focus the business to the internal pipeline programs within chronic inflammation. Aqilion has sold its holding to existing owners in Oncorena Holding AB.

“Aqilion was involved in starting Oncorena and has supported the company for a long time. It is positive for the company’s continued development that the existing life science specialized investors have acquired our holding and continue to actively support Oncorena in their future development,” says Sarah Fredriksson, CEO of Aqilion.

Oncorena is developing a new and potentially groundbreaking treatment for patients with advanced kidney cancer.

For further information, please contact:
Sarah Fredriksson, vd, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com
Gustaf Albèrt, CFO, AQILION AB, + 46 (0)709 168 302, gustaf.albert@aqilion.com